Evidence map›Paper›PMID 38644656›Full record

ArticleJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research2024

Actionable disease insights from bedside-to-bench investigation in fibrodysplasia ossificans progressiva.

Marc N Wein, Yingzi Yang

Registry-linked trialAbstract readEditorial
In one paragraph

Article in Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06508021 (A Phase 2/3, Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Part Study With Open-Label Extension), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06508021 phase2 / phase3active not recruitingnot on this map

A Phase 2/3, Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Part Study With Open-Label Extension (OLE) to Assess the Efficacy and Safety of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)

TypeinterventionalSponsorAshibio IncRan2024 to 2029Enrolled92ConditionsFibrodysplasia Ossificans ProgressivaArmsAndecaliximab, Placebo
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Marc N WeinEndocrine Unit, Harvard Medical School, Massachusetts General Hospital, Boston, MA 02114, United States.
Yingzi YangDepartment of Developmental Biology, Harvard School of Dental Medicine, Boston, MA 02115, United States.

Funding

Gas-Hedgehog signaling in intramembranous bone formation and expansionR01DE025866 · NIDCR · HARVARD MEDICAL SCHOOL · PI Yingzi Yang · 2016 to 2026
$5.3M
NIDCR NIH HHS R01 DE025866
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Myositis OssificansAnimalsHumansTranslational Research, Biomedical

Identifiers

PMID38644656
PMCPMC12147221

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.